Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM38KC
|
|||
| Drug Name |
ADP-A2M10
|
|||
| Drug Type |
CAR-T cell therapy
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1 | [1] | |
| Head and neck cancer [ICD-11: 2D42; ICD-9: 199] | Phase 1 | [1] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | ||
| Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1 | [2] | ||
| Company |
Adaptimmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanoma-associated antigen 10 (MAGEA10) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679. | |||
| REF 2 | Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581. | |||
| REF 3 | Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.